Oxaliplatin Sensitizes Human Colon Cancer Cells to TRAIL Through JNK-Dependent Phosphorylation of Bcl-xL
- 31 August 2011
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 141 (2), 663-673
- https://doi.org/10.1053/j.gastro.2011.04.055
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- The BCL-2 Family ReunionMolecular Cell, 2010
- Oxaliplatin enhances TRAIL‐induced apoptosis in gastric cancer cells by CBL‐regulated death receptor redistribution in lipid raftsFEBS Letters, 2009
- Identification of the Major Phosphorylation Site in Bcl-xL Induced by Microtubule Inhibitors and Analysis of Its Functional SignificancePublished by Elsevier BV ,2008
- TRAIL in cancer therapy: present and future challengesEmerging Therapeutic Targets, 2007
- Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIPMolecular Cancer Therapeutics, 2005
- Mechanisms of resistance to TRAIL-induced apoptosis in cancerCancer Gene Therapy, 2004
- Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapyCytokine & Growth Factor Reviews, 2003
- Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosisOncogene, 2001
- Translocation of SAPK/JNK to Mitochondria and Interaction with Bcl-xL in Response to DNA DamagePublished by Elsevier BV ,2000
- Two CD95 (APO-1/Fas) signaling pathwaysThe EMBO Journal, 1998